<DOC>
	<DOCNO>NCT01391507</DOCNO>
	<brief_summary>The purpose study investigate effect COR-1 combination standard therapy patient heart failure . The safety tolerability COR-1 also assess .</brief_summary>
	<brief_title>Pilot Study COR-1 Heart Failure</brief_title>
	<detailed_description>In patient dilate cardiomyopathy ( heart weaken enlarge ) , presence anti-beta1-receptor autoantibody show predict depressed leave ventricular function , increase prevalence serious ventricular arrhythmia , sudden cardiac death , cardiovascular mortality . In animal model , COR-1 cyclopeptide show bind , therefore decrease , anti-beta1-receptor autoantibody titre . This study investigate safety effectiveness COR-1 treatment patient dilate cardiomyopathy . This study randomize ( study treatment assign chance ) , double-blind , ( neither investigator patient know treatment volunteer receives ) , multicenter ( study conduct one center ) placebo-controlled ( one treatment inactive ) , parallel group study ( patient different treatment group receive medication time ) men woman heart failure due dilate cardiomyopathy . Eligible patient also leave ventricular ejection fraction less equal 45 % ( measurement percentage blood leave heart time contract ) positive anti-beta1-receptor autoantibody . The study consist 3 phase : screening phase , double-blind treatment period , follow-up phase . Patients randomly assign 1 4 treatment group : 20 mg COR-1 , 80 mg COR-1 , 160 mg COR-1 , placebo ( inactive medication ) . Each patient receive 1 intravenous dose ( medication inject vein ) every 4 week total 6 month . Patients come study center time receive study medication remain center 2 3 hour follow injection . Blood sample draw time point screen , treatment , follow-up period . Patients return study center follow-up visit 3 month follow completion 6-month treatment period . Patients participate study approximately 9 month . Patient safety monitor . The study drug ( COR-1 ) investigate treatment heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Diagnosed heart failure due dilate cardiomyopathy leave ventricular ejection fraction &lt; 45 % Presence antibeta1receptor autoantibodies New York Heart Association ( NYHA ) class II III heart failure Symptomatic heart failure &gt; 1 year &lt; 8 year Treatment adequate dos angiotensin convert enzyme inhibitor angiotensin II receptor blocker , betablockers , optional aldosterone antagonist accord guideline least six month ( exception lack tolerability drug ) stable dos 2 month prior screen Ischemic heart disease characterize &gt; = 50 % coronary artery stenosis and/or history myocardial infarction Third high degree valvular defect Any disease require immunosuppressive drug ( except &lt; = 5 mg/day prednisoneequivalent dose ) clinically relevant disorder immune system History severe allergy increase risk anaphylactic shock ( e.g. , bronchial asthma ) History , currently active illness , consider clinically significant Investigator illness Investigator considers exclude patient study could interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Anti-beta1-receptor autoantibody</keyword>
	<keyword>COR-1</keyword>
	<keyword>Heart failure</keyword>
</DOC>